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glucose metabolism; glucose uptake; glycogen CARDIOPROTECTION BY ADENOSINE is demonstrable in experimental models of ischemia-reperfusion injury, where it reduces infarct size and improves postischemic left ventricular (LV) mechanical function (12, 47) . Mechanisms underlying protection may involve alterations in energy supply (vasodilatation), energy demand (bradycardia and negative inotropy) (43), or energy substrate metabolism (glucose utilization). Although adenosine-induced cardioprotection is pronounced in hearts from healthy animals, results from clinical studies on the benefits of adenosine in diseased hearts have been less dramatic (31) . Similarly, the cardioprotective effectiveness of the indirect adenosine mimetic acadesine [5-aminoimidazole-4- carboxyamide-1-␤-D-ribofuranoside (AICAR)], an agent that increases adenosine release in ischemic tissue (34) , was limited in a phase III trial in patients undergoing coronary artery by-pass graft surgery (34a) . The mechanisms underlying the loss of adenosine-and acadesine-induced cardioprotection have not been clarified.
Previously, we observed a loss of the cardioprotective effectiveness of adenosine in hearts that were "stressed" by two transient (10-min) periods of ischemia before the onset of severe global ischemia and postulated that adenosine-induced cardioprotection may depend on the metabolic status of the heart (11) . Although transient ischemia per se has no effect on LV mechanical function, it reverses the effects of adenosine on glucose metabolism. Instead of an adenosine-induced inhibition of glycolysis observed in normal hearts (12) , adenosine stimulates glycolysis in stressed hearts, an effect that may contribute to acidosis and reduced cardioprotection (11) . Inasmuch as hearts stressed by transient ischemia may mimic some of the changes observed in the clinical setting, we utilized this experimental paradigm to determine signaling mechanisms that may account for changes in the metabolic responses to adenosine.
The stress-activated protein kinase 5Ј-AMP-activated protein kinase (AMPK) is an important regulator of energy metabolism and, when activated, inhibits ATP-consuming biosynthetic pathways while it activates ATP-generating catabolic processes (17) . During ischemia-reperfusion, activation of AMPK may be beneficial, by increasing ATP production via stimulation of glucose transport, glyocogenolysis, and glycolysis, as well as via stimulation of fatty acid oxidation through phosphorylation and inhibition of acetyl-CoA carboxylase (ACC) (3, 30, 32, 36, 39) . In contrast, activation of AMPK may be deleterious, inasmuch as stimulation of fatty acid oxidation leads to an inhibition of glucose oxidation (Randle cycle) (19, 40) , which, in combination with elevated rates of glycolysis (27) , promotes intracellular acidosis and Na ϩ and Ca 2ϩ overload, which in turn contribute to LV mechanical dysfunction during reperfusion (28) .
In this study, we investigated whether alterations in AMPK activity underlie changes in the effects of adenosine on energy substrate metabolism in hearts perfused aerobically after stress induced by transient ischemia. Our discovery that adenosine caused a marked activation of AMPK under these conditions allowed us to characterize further the effects of AMPK activation on carbohydrate and fatty acid metabolism under conditions of stable LV mechanical function. Specifically, this study tested the hypothesis that, in accordance with studies on ischemia-induced activation of AMPK, the activation of AMPK in response to adenosine in hearts stressed by transient ischemia also stimulates glycolysis, glucose uptake, and glycogenolysis. In addition, we tested the hypothesis that activation of AMPK in response to adenosine also accelerates myocardial fatty acid oxidation.
MATERIALS AND METHODS
Heart perfusions. All animals received humane care according to the guidelines of the Canadian Council on Animal Care and the University of Alberta Health Sciences Animal Welfare Committee. Hearts from pentobarbital sodium-anesthetized male Sprague-Dawley rats (300 -350 g body wt) that had been fed ad libitum were excised, and their aortae were cannulated and perfused with Krebs-Henseleit solution (37°C, pH 7.4, gassed with 95% O 2-5% CO2). The hearts were perfused in the Langendorff mode for 10 min and then switched to the working (ejecting) mode, as described previously (12) . The perfusate (recirculating volume of 100 ml) consisted of a modified Krebs-Henseleit solution containing 2.5 mM Ca 2ϩ , 11 mM glucose, 1.2 mM palmitate prebound to 3% BSA (fraction V), and 100 mU/l insulin. Perfusions were performed at a constant workload (11.5 mmHg preload and 80 mmHg afterload) and heart rate (paced at 300 beats/min). Heart rate and systolic and diastolic aortic pressures (mmHg) were measured using a pressure transducer (model P21, Gould) attached to the aortic outflow line. Cardiac output (ml/min) and aortic flow (ml/min) were measured using ultrasonic flow probes (model T206, Transonic) placed in the left atrial inflow line and the aortic outflow line, respectively. LV work (joules) was calculated as cardiac output ϫ LV developed pressure (systolic pressure Ϫ preload pressure)/1,000 ϫ 0.133 and served as a continuous index of LV mechanical function.
Perfusion protocol. Hearts were perfused under aerobic conditions in working mode for 45 min [normal group, no transient ischemia (ϪTI)] or under aerobic conditions for 15 min before stress by transient ischemia [stressed group, two 10-min periods of global no-flow ischemia, each followed by 5 min of reperfusion (ϩTI)]. The hearts were paced at 300 beats/min in all experimental groups, except during the periods of global no-flow ischemia. Normal and stressed hearts were then frozen for biochemical analyses (before treatment) or perfused aerobically for a further 35 min with vehicle (saline) or 500 M adenosine. Thereafter, untreated and adenosine-treated hearts were frozen for biochemical analyses (end treatment; Fig. 1A ). Two additional groups of stressed hearts were perfused aerobically during the 35-min treatment period with 1 M phentolamine or 1 M phentolamine ϩ 500 M adenosine.
Immunoblot analysis of AMPK and ACC. Heart homogenates were obtained by homogenization of frozen LV tissue in a solution containing 20 mM Tris ⅐ HCl (pH 7.4 at 4°C), 50 mM NaCl, 50 mM NaF, 5 mM sodium pyrophosphate, 0.25 mM sucrose, protease inhibitor cocktail (Sigma), phosphatase inhibitor cocktail (Sigma), and 1 mM dithiothrietol. After homogenization for 30 s, protein contents of the homogenates were determined using the Bradford protein assay. The samples were diluted and boiled in protein sample buffer, subjected to SDS-PAGE, and transferred to nitrocellulose, as previously described (42) . The membranes were blocked in 5% (wt/vol) skim milk powder in Tris-buffered saline (TBS) containing 0.1% (vol/vol) Tween and then immunoblotted with rabbit anti-phospho-AMPK (Thr 172 ) and rabbit anti-AMPK-total (1:1,000 dilution) in 5% BSA (wt/vol) in TBS or rabbit anti-phospho-ACC (Ser 79 , 1:1,000 dilution) in 5% BSA (wt/vol) in TBS and peroxidase-conjugated streptavidin (1:500 dilution) in 5% BSA (wt/vol) in TBS. After the membranes were extensively washed, they were incubated with a peroxidase-conjugated goat anti-rabbit secondary antibody in 5% skim milk powder (wt/vol) in TBS when appropriate. The membranes were washed further, and the antibodies were visualized using the Pharmacia enhanced chemiluminescence Western blotting and detection system. Densitometric analyses of immunoblots (n ϭ 3 per experimental group) were performed using Quantity One (version 4.4.0) software (Bio-Rad Laboratories). Densitometric values of the phosphorylated proteins were normalized to the total amount of the protein detected and expressed as arbitrary density units.
Measurement of AMPK activity. The activity of AMPK (nmol ⅐ mg protein Ϫ1 ⅐ min Ϫ1 ) was measured in 6% polyethylene glycol fractions extracted from 200 mg of frozen LV tissue, as described previously (25, 26) . Activity of AMPK in the presence of 5Ј-AMP (200 M) was assayed in the 6% polyethylene glycol fraction by following the Normal and stressed hearts were frozen for biochemical analyses (Prior to Treatment, arrows) or assigned randomly to a vehicle (saline)-treated group (n ϭ 9 for ϪTI, n ϭ 10 for ϩTI) or a group that was treated with 500 M adenosine (n ϭ 9 for ϪTI, n ϭ 7 for ϩTI) and perfused aerobically for another 35 (5, 14, 29, 44, 50, 60, 70 , and 80 min) was mixed with 1.88 ml of 1:2 (vol/vol) chloroform-methanol and 1.0 ml of chloroform and then 1.0 ml of 1.1 mol/l KCl-0.9 mol/l HCl was added. The samples were allowed to separate into polar and nonpolar phases. A 1.0-ml sample of the polar layer was removed and mixed with 1.0 ml of chloroform, 1.0 ml of methanol, and 0.9 ml of the KCl-HCl solution. Again samples were allowed to separate into polar and nonpolar phases, and 0.5-ml aliquots of the polar phase were subjected to scintillation counting for determination of 3 H2O content. 3 H2O content of the perfusate, indicative of the metabolism of [9,10- 3 H]palmitate, was determined in samples removed from the perfusate at 5, 14, 29, 44, 50, 60, 70, and 80 min and used to calculate steady-state rates of palmitate oxidation for the baseline and treatment periods.
Measurement of adenine nucleotide content. Adenine nucleotides were extracted from ϳ100 mg of frozen ventricular tissue into 1 ml of 6% ice-cold perchloric acid by homogenization with a pestle in a cold mortar. The tissue-perchloric acid mixture was centrifuged at 4°C, and the supernatant was neutralized with K 2CO3. High-performance liquid chromatography was used to measure nucleotide and nucleoside content in the neutralized extracts (10) .
Measurement of steady-state rates of glycolysis and glucose oxidation. Glycolysis and glucose oxidation rates were measured directly from the simultaneous production of 3 H2O (liberated at the enolase step of glycolysis) and 14 CO2 (liberated at the level of pyruvate dehydrogenase complex and in the citric acid cycle), respectively, from [5- 3 H]glucose and [U-14 C]glucose, as described previously (13, 15) . Perfusate was sampled at predetermined times (5, 14, 29, 44, 50, 60, 70, and 80 min), and steady-state rates (mol [5- 3 H]glucose or [U- 14 C]glucose metabolized ⅐ g dry wt Ϫ1 ⅐ min Ϫ1 ) were calculated for baseline and treatment periods.
Calculation of rate of proton production arising from exogenous glucose metabolism. When glucose (from endogenous or exogenous sources) is metabolized by glycolysis and subsequently oxidized 1:1, with the associated synthesis and hydrolysis of ATP, the net production of protons is zero. However, if the rate of glycolysis exceeds that of glucose oxidation, there is a net production of two protons per molecule of exogenous glucose that passes through glycolysis, which is not subsequently metabolized. Therefore, the rate of proton production attributable to the hydrolysis of ATP arising from exogenous glucose metabolism can be calculated as follows: 2 ϫ (rate of glycolysis Ϫ rate of glucose oxidation).
Assay of glycogen content and glucose uptake. Frozen LV tissue was powdered using a mortar and pestle maintained at the temperature of liquid N 2. Glycogen, in 200 mg of powdered tissue, was converted to glucose by reaction with 4 M H2SO4. The amount of glucose (mol glucose units/g dry wt) thus obtained was determined using a Sigma glucose analysis kit. The net rate of glycogen synthesis (mol glucose ⅐ min Ϫ1 ⅐ g dry wt Ϫ1 ) in hearts during the 35-min aerobic treatment period was calculated from the increase in [5- 3 H]-and [ 14 C]glucosyl units in total myocardial glycogen in hearts frozen at the end of treatment relative to hearts frozen before treatment. The rate of glucose uptake (mol ⅐ min Ϫ1 ⅐ g dry wt Ϫ1 ) during the treatment period was calculated as the sum of the net rate of glycogen synthesis and the rate of glycolysis in individual hearts. The net rate of glycogen degradation was calculated as the difference between the unlabeled myocardial glycogen content in the before-treatment and end-treatment groups.
Materials. Statistical analysis. Values are means Ϯ SE of n observations. The significance of differences between untreated and adenosine-treated groups was estimated by Student's t-test. When required, multiple comparisons were made using one-way ANOVA. When ANOVA revealed significant differences, individual groups were compared using Bonferroni's multiple comparisons test. Differences were considered significant when P Ͻ 0.05.
RESULTS
LV work in normal and stressed hearts. LV work was stable and similar in normal and stressed hearts before they were assigned to the vehicle-or adenosine-treated groups. Although all measurable LV work ceased during the periods of transient ischemia, it recovered quickly and remained stable throughout subsequent perfusion in the absence (vehicle-treated) or presence of adenosine. Adenosine had no effect on LV work in normal or stressed hearts (Fig. 1B) . Coronary flow and coronary vascular conductance were increased by adenosine (P Ͻ 0.05) in normal, but not in stressed, hearts ( Table 1) .
Phosphorylation of AMPK and ACC in normal and stressed hearts. To determine the consequences of transient ischemia per se, phosphorylation of AMPK and its downstream target ACC was assessed in normal and stressed hearts frozen before the treatment period. Because there was no difference in AMPK ( Fig. 2A) or ACC (Fig. 2B ) phosphorylation between these groups, data presented hereafter pertain specifically to alterations in AMPK phosphorylation and cardiac energy metabolism in response to adenosine treatment.
Effects of adenosine on phosphorylation of AMPK and ACC. Adenosine decreased AMPK phosphorylation by 70% and activity by 50% in normal hearts (P Ͻ 0.05, by unpaired t-test), consistent with our previous study in which we used N Values are means Ϯ SE; n, number of hearts. TI, transient ischemia; HR, heart rate; RPP, rate-pressure product; PSP, peak systolic pressure; AF, aortic flow; CF, coronary flow; CVC, coronary vascular conductance. *Significantly different from vehicle. †Significantly different from adenosine ϩ TI.
cyclohexyladenosine, an adenosine A 1 receptor agonist (15) . Adenosine increased AMPK phosphorylation (9-fold) and activity (2.3-fold) in stressed hearts (P Ͻ 0.05; Fig. 3 ). AMPK phosphorylation and activity were 30-and 6-fold higher, respectively, in adenosine-treated stressed hearts than in adenosine-treated normal hearts (Fig. 3) .
The short-term regulation of fatty acid oxidation is, in part, achieved via the reversible phosphorylation and inactivation of ACC. Adenosine inhibited the phosphorylation of ACC ␤-and ␣-isoform in normal hearts (Fig. 4A) ; however, as we reported previously (8), it did not affect rates of palmitate oxidation (Fig. 4B) . Interestingly, despite the marked adenosine-induced activation of AMPK in stressed hearts, adenosine did not increase the phosphorylation of ACC ␤-or ␣-isoform, nor did it accelerate rates of palmitate oxidation.
Effects of adenosine on adenine nucleotide content. Inasmuch as an increase in AMP concentration and/or a decrease in the ATP-to-AMP ratio regulates AMPK activity, the contents of these adenine nucleotides were assessed in vehicle-and adenosine-treated hearts. Although adenosine did not affect ATP content in stressed hearts (Fig. 5A) , it increased AMP content 1.6-fold (P Ͻ 0.05; Fig. 5B ) and, consequently, decreased the ATP-to-AMP ratio by 40% (P Ͻ 0.05; Fig. 5C ), thereby mimicking changes expected to occur with a decrease in cellular energy state. Although adenosine increased AMP content of normal hearts, it also increased ATP content and, therefore, did not change the ATP-to-AMP ratio (data not shown).
Effects of AMPK activation on glucose metabolism. Steadystate rates of glucose metabolism (glycolysis and glucose oxidation) and calculated rates of proton production were assessed to characterize the consequences of the adenosineinduced activation of AMPK in stressed hearts. Because the rates of glycolysis (1.8-fold, P Ͻ 0.05) and glucose oxidation (1.8-fold, P Ͻ 0.05) were accelerated in hearts with elevated AMPK activity (Fig. 6, A and B) , the calculated rate of proton production from exogenous glucose was significantly greater (1.7-fold, P Ͻ 0.05; Fig. 6C) .
Effects of AMPK activation on glucose uptake and glycogen metabolism. Rates of glucose uptake, as well as glycogen synthesis and degradation, were also calculated in hearts perfused in the absence and presence of adenosine. Despite the marked activation of AMPK in adenosine-treated hearts, the rate of glucose uptake was not different from that calculated in vehicle-treated hearts (Fig. 7A) . Inasmuch as an increase in glucose uptake was not responsible for the elevated rate of glycolysis observed in hearts with high AMPK activity, glycogen metabolism (glycogen synthesis and glycogen degradation) was assessed. In vehicle-treated hearts, the net rate of glycogen synthesis was ϳ22% of the rate of glucose uptake. In hearts with high AMPK activity, glycogen synthesis was completely suppressed (P Ͻ 0.05; Fig. 7B) ; consequently, the rates of glucose uptake (Fig. 7A) and glycolysis (Fig. 6A) were equivalent. The net rate of glycogenolysis was not different between hearts with low and high AMPK activity (Fig. 7C) . Inhibition of glycogen synthesis and unaltered glycogen degradation in hearts with high AMPK activity resulted in a slight, but not statistically significant, decrease in glycogen content at the end of the treatment period in adenosine-treated hearts (Fig.   7D ). Overall, these data suggest that an alteration in glucose utilization, i.e., the partitioning of glucose between glycogen synthesis and glycolysis after uptake, rather than an increase in glucose uptake, accounts for the acceleration of glycolysis in hearts with high AMPK activity.
Effects of AMPK activation on steady-state rates of ATP production. The activation of AMPK by adenosine in stressed hearts significantly increased calculated rates (mol⅐g dry wt Ϫ1 ⅐min Ϫ1 ) of ATP production from glycolysis (from 6.1 Ϯ 1.1 to 10.9 Ϯ 0.9, P Ͻ 0.05) and glucose oxidation (from 21.1 Ϯ 2.6 to 35.5 Ϯ 4.9, P Ͻ 0.05) but had no significant effect on the calculated rate of ATP production from palmitate oxidation (from 115.5 Ϯ 19.4 to 133.8 Ϯ 21). Inasmuch as palmitate oxidation is the major energy source, overall ATP production was not increased in hearts with high AMPK activity.
Effects of phentolamine on AMPK phosphorylation. We previously demonstrated that phentolamine (1 M), an ␣-ad- renoceptor antagonist, prevents the adenosine-induced acceleration of glycolysis and the calculated rate of proton production in hearts stressed by transient ischemia (9) . Examination of the effects of phentolamine on the phosphorylation of AMPK showed that although it has no effect on AMPK phosphorylation per se, it prevented the adenosine-induced increase in AMPK phosphorylation in stressed hearts (Fig. 8) .
DISCUSSION
This study investigated the role of AMPK in mediation of the effects of adenosine on myocardial energy metabolism. During aerobic perfusion of hearts stressed by transient ischemia and under conditions of stable mechanical function, adenosine stimulated AMPK activity. Despite the marked increase in AMPK activity, ACC phosphorylation and palmitate oxidation were not affected. However, increases in glycolysis and glucose oxidation were observed. Inasmuch as glucose uptake in hearts with high AMPK activity was unchanged, the observed increase in glucose metabolism arose from an altered partitioning of glucose after its uptake away from glycogen synthesis to glycolysis and glucose oxidation. This indicates that, in contrast to the ischemia-induced activation of AMPK, adenosine-induced activation of AMPK under conditions of stable LV work is not sufficient to stimulate fatty acid oxidation or glucose uptake. Thus previous associations between high AMPK activity and elevated rates of fatty acid oxidation and glucose uptake in ischemic tissue may have arisen as a consequence of other ischemia-induced changes, rather than a direct activation of AMPK.
These studies were performed using isolated working rat hearts, a well-established model for the simultaneous and direct measurement of cardiac mechanical and metabolic function. The inclusion of glucose and palmitate as energy substrates in the perfusate ensured that myocardial glycogen content was not depleted, thereby preserving normal values of glycogen turnover (11, 14) . The presence of insulin ensured adequate glucose transport, so that glucose availability was not rate limiting for glycolysis and glucose oxidation. Furthermore, the concentrations of energy substrates provided in the perfusate mimic some of the metabolic conditions that occur after myocardial ischemia. The periods of transient ischemia that caused alterations in the responses to adenosine do not induce ischemic preconditioning, inasmuch as recovery of LV mechanical function after a period of sustained severe ischemia is unaltered (11) . Also, inasmuch as transient ischemia is not of sufficient duration to cause LV mechanical dysfunction during the treatment periods, this experimental model provided the opportunity to characterize the role of AMPK in mediating adenosine-induced alterations in energy substrate metabolism under aerobic conditions of stable energy supply and demand.
Examination of AMPK phosphorylation status (indicative of activity) and direct assays of AMPK activity provide clear evidence that, relative to vehicle-treated hearts, adenosine increased AMPK activity in hearts stressed by transient ischemia. Activation of AMPK was not due to transient ischemia per se, inasmuch as AMPK phosphorylation after transient ischemia, but before adenosine treatment, was identical to that in normal hearts. The mechanism underlying the activation of AMPK by adenosine is unlikely to be mediated by adenosine A 1 receptors, inasmuch as the A 1 receptor agonist N 6 -cyclohexyladenosine inhibits AMPK activation in isolated working rat hearts during low-flow ischemia as well as after transient ischemia (13, 15) . Adenosine A 2 receptor stimulation is also not likely involved, inasmuch as the selective adenosine A 2 receptor agonist CGS-21680 inhibits AMPK activation (4). Stimulation of ␣-adrenoceptors activates AMPK in Chinese hamster ovary cells (24) , and we previously implicated ␣-adrenoceptors in adenosine-induced stimulation of glycolysis following transient ischemia (9) . In this study, we have demonstrated that the ␣-adrenoceptor antagonist phentolamine, which prevents the adenosine-induced stimulation of glycolysis after transient ischemia (9), also abrogates the phosphorylation of AMPK in response to adenosine in stressed hearts. This suggests that activation of ␣-adrenoceptors plays a role in the adenosine-induced activation of AMPK and supports the notion that the associated downstream alterations in myocardial glucose metabolism were due to AMPK activation.
Although the use of AICAR is precluded in this study because of its marked depressant effects on LV function at concentrations required to enhance AMPK activity, AICAR was used in previous studies to activate AMPK independent of ischemia, possibly by mimicking ischemic conditions by decreasing the ATP-to-AMP ratio. The activation of AMPK by adenosine in hearts stressed by transient ischemia may involve a similar mechanism. Although tissue levels of phosphocreatine and creatine and the phosphocreatine-to-creatine ratio (Table 2) , as well as ATP content, were not significantly different between groups at the end of the treatment period, the higher AMP content in adenosine-treated hearts, as well as the decreased ATP-to-AMP ratio, suggests that, in the isolated perfused rat heart, AMP is capable of surmounting ATPmediated inhibition of AMPK activity. Although the measurement of total AMP content by high-pressure liquid chromatography in this study may overestimate free cytosolic AMP concentration, inasmuch as most AMP is bound, our findings are consistent with a previous report suggesting that ATP inhibition of AMPK activity can be overcome by a small (ϳ1.8 M) change in the free cytosolic concentration of AMP (16) . The elevated AMP content in hearts treated with adenosine after transient ischemia (Fig. 5B) may be attributed to an increased influx of adenosine from the vascular compartment into the cardiac myocyte and subsequent phosphorylation by adenosine kinase (7) . This is demonstrated by the increase in total tissue content of adenosine (data not shown) as well as AMP. AMPK activation in response to a significant change in Values are means Ϯ SE measured in stressed hearts frozen at the end of treatment. PCr, phosphocreatine; Cr, creatine. There were no significant differences between groups. the ATP-to-AMP ratio may rule out a role for Ca 2ϩ /calmodulin-dependent protein kinase kinases as AMPK-activating kinases under these conditions, inasmuch as Ca 2ϩ /calmodulindependent protein kinase kinases appear to activate AMPK independent of changes in the ATP-to-AMP ratio and are not influenced by AICAR (21) .
Numerous reports have linked AMPK activation to the stimulation of fatty acid oxidation. AMPK activation has been associated with enhanced clearance of long-chain fatty acid in cardiac muscle preparations in vivo (41) and with increased rates of myocardial fatty acid oxidation during postischemic reperfusion (25) . However, it was not clearly defined whether enhanced fatty acid utilization was due solely to AMPK activation, rather than other changes that may have occurred as a consequence of ischemia and altered LV mechanical function. The lack of association between AMPK activation and a stimulation of the rate of palmitate oxidation observed in this study indicates that AMPK activation is not sufficient to stimulate fatty acid oxidation in the aerobically perfused working rat heart. Moreover, although the underlying mechanism for the stimulation of fatty acid oxidation by AMPK has been considered to result from AMPK-induced phosphorylation and inactivation of ACC, the extent of ACC (␣-and ␤-isoforms) phosphorylation was unaltered in the face of markedly elevated AMPK activity. Furthermore, although the phosphorylation of ACC is attenuated in response to adenosine in normal hearts (absence of transient ischemia), there is no associated change in palmitate oxidation. These observations differ from previous reports that suggested a negative correlation between AMPK and ACC activity, coupled to increased fatty acid oxidation (25, 32, 33, 36, 46) . However, these differences may arise because of differences in experimental models (skeletal vs. cardiac muscle and severity of myocardial ischemia). Moreover, the dissociation between AMPK and ACC phosphorylation in this study is consistent with a recent report indicating a lack of ACC phosphorylation, despite AMPK activation in rat heart after mild ischemia (1) .
After entry into the cardiac myocyte, ϳ80% of glucose enters the glycolytic pathway, which generates a limited amount of ATP (2 mol/mol glucose) and pyruvate for subsequent oxidation. The observation that glycolysis was accelerated in hearts with high AMPK activity is compatible with previous observations that indicate AMPK stimulation of the phosphorylation and activation of 6-phosphofructo-2-kinase, an enzyme that generates fructose 2,6-bisphosphate, a potent stimulator of 6-phosphofructo-1-kinase, the rate-limiting step of glycolysis (6, 30) . Glucose oxidation, the final stage of glucose metabolism, at which pyruvate undergoes oxidative decarboxylation by pyruvate dehydrogenase to generate acetylCoA for the tricarboxylic acid cycle, was also accelerated by adenosine. Although previous studies suggest that increasing glycolysis during ischemia and reperfusion plays a protective role in limiting myocardial damage (39) , the associated increase in the calculated rate of proton production and potential for Na ϩ and Ca 2ϩ overload (28) may explain the loss of cardioprotective effectiveness of adenosine in stressed hearts, as reported previously (11) .
The ability to activate AMPK in the absence of confounding factors that occur 1) during severe ischemia, 2) with alterations in mechanical function and energy demand, or 3) in isolated cell systems (low energy demand) provided a unique opportunity to characterize the relationships between AMPK activity and the pathways of glucose uptake and glycogen metabolism under conditions of stable LV work. Acceleration of myocardial glucose uptake by various stresses is independent of insulin signaling and may be due to the activation of AMPK (18, 38, 54) . Indeed, activation of AMPK by metabolic stresses in isolated skeletal muscle, or pharmacologically in isolated heart muscle by AICAR, stimulates glucose uptake, which may result from an AMPK-mediated translocation of GLUT4 transporters from an intracellular membrane pool to the cell surface (23, 35, 38) . Whether activation of AMPK alone is sufficient to increase glucose uptake in the absence of ischemia or changes in energy demand has not been clearly defined. However, this study has shown that, despite marked increases in AMPK activity, glucose uptake was not markedly affected. The low statistical power of this comparison may have concealed a significant increase, but the observed 15% difference was small relative to the more than twofold increase in glucose uptake that can be achieved in the absence of palmitate (42) . That result also indicates that the lack of effect of AMPK activation on glucose uptake was not due to maximal rates of uptake preexisting in the working heart. Thus it appears that AMPK activation is not sufficient to stimulate glucose uptake in working cardiac muscle in the absence of other stimuli that may occur concomitantly with ischemia. This finding is in agreement with a recent study that demonstrated that AMPK activation does not affect cardiac glucose clearance in vivo (41) . Furthermore, in contrast to previous reports linking increased glucose uptake and elevated rates of glycolysis (6, 20, 30) , the present study indicates that increased glucose uptake does not underlie the acceleration of glycolysis in response to the adenosine-induced activation of AMPK, suggesting that these two processes are differentially regulated under conditions of stable LV work.
Glycogen is an important source of endogenous glucose, and its turnover (simultaneous synthesis and degradation) is a key factor in the control of glucose utilization (14, 15) . Glycogen accumulates to physiological levels (150 -160 mol/g dry wt) in aerobic working rat hearts perfused with glucose, insulin, and palmitate, and although there is continuous glycogen turnover, the net rate of glycogenolysis is negligible (14) . The demonstration that net glycogen synthesis was depressed in hearts with high AMPK activity, whereas glycogenolysis was unaffected, reflects an altered partitioning of glucose utilization after uptake in hearts with elevated AMPK activity. This may arise because of suppression of glycogen synthase activity (2, 45) , thereby directing glucose away from energy storage (glycogen synthesis), or by an activation of glycolysis, thereby diverting glucose toward energy production (glycolysis and glucose oxidation).
In conclusion, this study has shown that the activation of AMPK by adenosine during aerobic perfusion and under conditions of stable energy supply and demand does not alter overall rates of energy production. Rather, activation of AMPK stimulates glycolysis and glucose oxidation and accelerates the calculated rate of proton production but has no effect on rates of glucose uptake and palmitate oxidation. This indicates that AMPK regulates myocardial glucose utilization in a coordinated manner by influencing the relative rates of glycolysis and glycogen synthesis. Inasmuch as AMPK activation increases the calculated rate of proton production and the potential for acidosis, inhibition of AMPK may be a useful approach to restore adenosine-induced cardioprotection in stressed hearts.
